LantheusLNTH
About: Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Employees: 808
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
57% more call options, than puts
Call options by funds: $42.5M | Put options by funds: $27.1M
13% more repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 169
2.33% more ownership
Funds ownership: 114.51% [Q1] → 116.84% (+2.33%) [Q2]
10% less funds holding
Funds holding: 514 [Q1] → 464 (-50) [Q2]
13% less capital invested
Capital invested by funds: $7.64B [Q1] → $6.62B (-$1.03B) [Q2]
46% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 87
60% less funds holding in top 10
Funds holding in top 10: 10 [Q1] → 4 (-6) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Truist Securities Richard Newitter | 12%upside $63 | Hold Downgraded | 12 Aug 2025 |
JMP Securities David Turkaly | 30%upside $73 | Market Outperform Maintained | 7 Aug 2025 |
Mizuho Anthony Petrone | 25%upside $70 | Outperform Maintained | 7 Aug 2025 |
B. Riley Securities Justin Walsh | 95%upside $109 | Buy Maintained | 23 Jun 2025 |
Financial journalist opinion
Based on 10 articles about LNTH published over the past 30 days
